Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Trial Profile

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Therapeutic Use
  • Sponsors Upsher-Smith
  • Most Recent Events

    • 30 Jun 2009 Results of a secondary analysis presented at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) according to an Upsher-Smith media release.
    • 17 Feb 2009 Results published in Menopause: Journal of the North American Menopause Society, according to a Upsher-Smith media release.
    • 25 Sep 2008 Results of additional analyses were presented at the North American Menopause Society's 19th Annual Meeting. These analyses investigated the effects of uterine status, age and body mass index on response to treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top